Trial reportPsychopharmacology2011
Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression.
Trial report in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Measurement methods of BDNF levels in major depression: a qualitative systematic review of clinical trials.The Psychiatric quarterly · 2013Pooled it
- Serum BDNF levels before treatment predict SSRI response in depression.Progress in neuro-psychopharmacology & biological psychiatry · 2011Trial
- Plasma and Platelet Brain-Derived Neurotrophic Factor (BDNF) Levels in Bipolar Disorder Patients with Post-Traumatic Stress Disorder (PTSD) or in a Major Depressive Episode Compared to Healthy Controls.International journal of molecular sciences · 2024Article
- Psychopharmacological Approaches for Neural Plasticity and Neurogenesis in Major Depressive Disorders.Advances in experimental medicine and biology · 2024Review
- Variation of Circulating Brain-Derived Neurotrophic Factor (BDNF) in Depression: Relationships with Inflammatory Indices, Metabolic Status and Patients' Clinical Features.Life (Basel, Switzerland) · 2023Article
- Ferroptosis-related genes as diagnostic markers for major depressive disorder and their correlations with immune infiltration.Frontiers in medicine · 2023Article
- Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology.Diagnostics (Basel, Switzerland) · 2021Article
- Identification of Diagnostic Markers for Major Depressive Disorder Using Machine Learning Methods.Frontiers in neuroscience · 2021Article
- Beyond Haemostasis and Thrombosis: Platelets in Depression and Its Co-Morbidities.International journal of molecular sciences · 2020Review
- Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer.International journal of molecular sciences · 2020Review
- Depression and Cardiovascular Disease: The Viewpoint of Platelets.International journal of molecular sciences · 2020Review
- Brain-derived neurotrophic factor in heart failure.Anatolian journal of cardiology · 2019Article
- Peripheral Blood Brain-Derived Neurotrophic Factor as a Biomarker of Alzheimer's Disease: Are There Methodological Biases?Molecular neurobiology · 2018Review
- The Correlations among Depressive Symptoms, Cognitive Performance and Serum BDNF Levels in the Patients with Chronic Kidney Disease.Psychiatry investigation · 2018Article
- Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation?World journal of psychiatry · 2016Review
- Antidepressants and anti-inflammatory drugs differentially reduce the release of NGF and BDNF from rat platelets.Pharmacopsychiatry · 2013Article
- Platelets and depression in cardiovascular disease: A brief review of the current literature.World journal of psychiatry · 2012Review
- Platelet protein kinase C and brain-derived neurotrophic factor levels in borderline personality disorder patients.Psychiatry research · 2012Article
- Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features.Therapeutic advances in psychopharmacology · 2012Article
- Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.Psychopharmacology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroplastic processes are thought to be involved in the pathophysiology of major depression. It has been reported that serum brain-derived neurotrophic factor (BDNF) is decreased in depressed patients.
objectivesCompare BDNF levels in depressed patients and healthy controls in platelet poor plasma and in washed platelets. Observe the effects of 8- and 24-week treatment with S-citalopram on these levels.
methodsWe assessed the levels of BDNF in platelet poor plasma and in washed platelets from 18 major depression patients, and compared them with 14 healthy controls. Blood samples were obtained from patients before and during treatment (8 and 24 weeks) with a selective serotonin reuptake inhibitor, S-citalopram.
resultsA significant decrease in severity of depressive symptoms was observed from the first month of treatment with S-citalopram, and symptoms continued decreasing until the 6th month. Plasma BDNF levels in untreated patients appeared significantly increased (p<0.01) but reached values similar to those of controls at the 24th week. In contrast, levels of platelet BDNF appeared significantly decreased (p<0.05), but treatment also normalized levels so that values obtained were equivalent to those of controls.
conclusionsUntreated depressed patients showed increased plasma BDNF levels and decreased platelet BDNF levels, as compared with control subjects, and tend to normalize during treatment with S-citalopram for 24 weeks, with BDNF reaching levels similar to those in healthy controls at the 24th week in both samples. We observed that improvement in depressive symptoms was accompanied by normalization of plasma and platelet BDNF levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.